Innovations in GLP-1 Receptor Agonist Therapy: Patient-Centered Strategies to Overcome Barriers and Reduce Cardiometabolic Risk in Type 2 Diabetes Mellitus Webcast Post-Test

Question Title

* 1. After this session, please rate how your level of confidence changed.

Feel no more confident than before.

Feel a little more confident than before.

Feel somewhat more confident.

Feel more confident than before.

Feel a lot more confident than before.

Question Title

* 2. There are an estimated 30.3 million individuals in the US with diabetes, many of whom lack access to specialized care. According to a recent Association of American Medical Colleges report, approximately how many active US physicians specialize in endocrinology, diabetes, and/or metabolism?

7,500

15,000

30,000

Question Title

* 3. Which of the following is true with regard to the relationship between GLP-1 RA duration and associated changes in FPG and PPG?

Long-acting agents have a greater lowering impact on FPG vs PPG

Short-acting agents have a greater lowering impact on PPG vs FPG

Short- and long-acting agents have a similar lowering effect on both FPG and PPG

Question Title

* 4. According to current AACE/ACE guidelines, what is the LDL-C target level for a patient with very high ASCVD risk?

<100 mg/dL

<70 mg/dL

<55 mg/dL

Question Title

* 5. Approximately what percentage of patients with T2DM report that they are trying to lose weight?

30%

50%

70%

Question Title

* 6. Which of the following medications would you be most likely to prescribe for a patient with T2DM, established CAD and CKD, and history of HF?

GLP-1 RA

SGLT2 inhibitor

DPP4 inhibitor